AI Article Synopsis
- Astrocytoma is the most prevalent brain tumor in adults, with glioblastoma being the most lethal form, and current treatment advancements have not significantly improved survival rates.
- Genetic biomarkers like microRNAs, circulating tumor DNA, and long noncoding RNA show promise for diagnosing and treating astrocytoma but face challenges in clinical application.
- The review explores liquid biopsies as innovative tools for managing astrocytoma, highlighting the necessity for standardized protocols and further research to enhance their clinical effectiveness.
Article Abstract
Astrocytoma is the most common adult brain tumor, with glioblastoma being the deadliest neuro-related malignancy. Despite advances in oncology, the prognosis for astrocytoma, especially glioblastoma, remains poor, and tracking disease progression is challenging due to a lack of robust biomarkers. Genetic biomarkers, including microRNAs, cell-free DNA, circulating tumor DNA, circular RNA, and long noncoding RNA, can serve as potential diagnostic and therapeutic targets. In this review, we examine the existing literature, analyzing the various less established liquid and tumor genetic biomarkers and their potential to act as diagnostic, prognostic, and therapeutic targets. We highlight the clinical challenges and limitations in implementing liquid biopsy strategies in clinical practice. The article discusses the potential of liquid biopsies as valuable tools for personalized astrocytoma management while emphasizing the need for standardized protocols and further advancements to establish their clinical utility and therapeutic application.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.wneu.2024.06.009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!